Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000852

Drug Information
NameDihydroergotoxine
SynonymsNCGC00017400-06; Ergotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'alpha,10alpha)-; Orstanorm; Dihidroergotamina; IDI1_000592; Ergont; (10alphaH)-5'alpha-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman; DET MS; DivK1c_000592; Diergo; SPBio_001235; CHEBI:4562; Ambotz511-12-6; DIHYDROERGOTOXINE; 9,10-dihydro-ergotamine; KBio2_006673; Diidroergotamina; CID10531; dihydroergotamine; BSPBio_002209; UNII-436O5HM03C; Dergotamine; Verladyn; 11032-41-0; 9,10-Dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione; D07837; NINDS_000592; KBio1_000592; KBio3_001429; LS-61979; Spectrum_001057; Ergot Alkaloids, Hydrogenated; Dihidroergotamina [INN-Spanish]; Migranal; CHEBI:658566; Dirgotarl; Spectrum4_000958; C07798; Spectrum2_001188; Dehydroergotamine; C33H37N5O5; Dihydroergotaminum [INN-Latin]; Seglor; Endophleban; Lopac0_000357; 5'-Benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman; CID517557; AC1L1VEA; 511-12-6; Ikaran; BIDD:GT0120; CHEMBL1732; BRD-K72166146-066-02-1; Ergomimet; Angionorm; Morena; LS-64563; Co-Dergocrine; Spectrum3_000395; BRN 5720196; Ergoloid dihydroergotoxine; Ergoloid Mesylates (dihydroergotoxine); Agit; Dihydroergotoxin; AC1LAOVT; KBio2_004105; Ergotamine, 9,10-dihydro-; Dihydroergotamine methanesulfonate; KBio2_001537; DB00320; D.H.E.; KBioSS_001537; Ergotonin; DHE-45; 9,10-Dihydroergotamine; Neomigran; 6190-39-2 (mesylate); Dihydroergotaminum; Spectrum5_000905; KBioGR_001576; Dihydroergotamine (INN); Tonopres; (5'alpha)-12'-Hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione; Ergotamine, dihydro, methanesulfonate (salt); Dihydergot; Neomigran (TN); Diidroergotamina [DCIT]; (5'alpha)-5'-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxoergotaman; EINECS 208-123-3; Ergotoxine, dihydro-
IndicationAlzheimer's disease
[ICD9: 331.0   ICD10: G30]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C33H37N5O5.CH4O3S/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)
20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30
(40)37-13-7-12-27(37)33(38,42)43-32;1-5(2,3)4/h3-6,8-11,17,21,23,
25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39);1H3,(H,2,3,4)
InChIKeyADYPXRFPBQGGAH-UHFFFAOYSA-N
Canonical SMILESCC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CC6C(CC7=CNC8=CC=
CC6=C78)N(C5)C.CS(=O)(=O)O    
Therapeutic ClassVasodilator Agents
CAS NumberCAS 11032-41-0
FormulaC34H41N5O8S
PubChem Compound IDCID 517557.
PubChem Substance IDSID 168192.
SuperDrug ATC IDC04AE01; N02CA01
N02CA01
TargetDopamine D2 receptorAgonist[1]
Gamma-aminobutyric-acid type A (GABA(A)) receptorAgonist[1]
Ref 1Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543